Your session is about to expire
← Back to Search
Pazopanib for Von Hippel-Lindau Disease
Study Summary
This trial looks at the side effects and effectiveness of pazopanib hydrochloride for patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop cancer cell growth by blocking some enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 22 Patients • NCT01247571Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants have been enrolled in this trial thus far?
"Unfortunately, this medical study is not presently accepting patients. It was initially posted on January 17th 2012 and revised most recently on October 11th 2022. If you are seeking alternative trials to participate in, there exist 1386 studies for von hippel-lindau disease as well as 24 related to Pazopanib Hydrochloride which are currently enrolling participants."
Has Pazopanib Hydrochloride been authorized for release by the FDA?
"The safety of Pazopanib Hydrochloride is estimated to be a 2 on the scale of 1-3. This is because Phase 2 trials have not generated any confirmations in regards to efficacy, but there are some indications that it can provide safety benefits."
Is the enrollment period for this clinical trial still open?
"This medical trial is no longer accepting patients. The first posting of the study was on January 17th 2012 and it was last modified on October 11th 2022. However, for those interested in other studies related to von hippel-lindau disease or Pazopanib Hydrochloride, there are currently 1386 trials recruiting participants and 24 respective clinical studies that remain active."
Has this medical research been conducted before?
"At present, 24 studies for Pazopanib Hydrochloride are still active and can be found in 23 countries across 608 cities. The initial trial was launched by Novartis in 2011 and it successfully passed Phase 2 drug approval with 180 participants involved. Since then, another 726 trials have been conducted on the medication."
Share this study with friends
Copy Link
Messenger